21 results
424B3
QTTB
Q32 Bio Inc.
29 Apr 24
Prospectus supplement
5:10pm
.
Our Strategy
Our mission is to develop therapeutics that restore healthy immune regulation for patients with severe autoimmune and inflammatory
8-K
EX-99.3
QTTB
Q32 Bio Inc.
26 Mar 24
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
9:57pm
Innovation Fund and Sanofi Ventures.
Our Strategy
Our mission is to develop therapeutics that restore healthy immune regulation for patients with severe
8-K
EX-99.1
QTTB
Q32 Bio Inc.
26 Jan 24
Regulation FD Disclosure
4:13pm
capital structure. 4
Q32 Mission: Building The Future of Immune Therapeutics Bempikibart (ADX-914): Dual inhibitor of IL-7 and TSLP signaling, designed … basket Anticipated Milestones 1. Assuming closing mid-1Q 2024. * Based on current management estimates 34
Q32 Mission: Building The Future of Immune
425
QTTB
Q32 Bio Inc.
26 Jan 24
Business combination disclosure
12:00am
in which we will operate, developments in our business and operations and changes in our capital structure. 4
Q32 Mission: Building The Future … . * Based on current management estimates 34
Q32 Mission: Building The Future of Immune Therapeutics Bempikibart (ADX-914): Dual inhibitor of IL-7
425
x5p605ldwh9q0fywug7k
16 Nov 23
Business combination disclosure
4:19pm
425
8z4nl39s 9q
16 Nov 23
Business combination disclosure
7:17am
8-K
EX-99.2
phlygny5ape
16 Nov 23
Q32 Bio and Homology Medicines Announce Merger Agreement
7:16am
8-K
EX-99.1
dl0x8j4imoyku4f
8 Feb 21
Other Events
4:07pm
8-K
EX-99.1
bfw9xa
6 Jan 21
Regulation FD Disclosure
8:01am